Compare Abeona Therapeutics Inc (ABEO) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs FTAI Aviation Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while FTAI Aviation Ltd trades at $212.87 (market cap $23.33B). The key difference: FTAI Aviation Ltd is far larger — about 62.5× Abeona Therapeutics Inc's market cap, and FTAI Aviation Ltd pays a 0.66% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FTAI | |
|---|---|---|
Market Cap | $373.32M | $23.33B |
Sector | Health | Industrials |
52-Week High | $7.23 | $310.04 |
52-Week Low | $4.17 | $109.76 |
Enterprise Value | $228.22M | $26.37B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FTAI Aviation trades at $241.54, down 2.63% amid a bearish technical signal, though it remains supported by strong profitability with a 34.99% gross margin and 226.91% ROE. Recent earnings have missed expectations, but revenue growth is projected to rise from $2.51B in 2025 to $2.8B in 2026. Positive news includes a strategic collaboration for Boeing 737-800 freighters and a $0.45 dividend announcement.
The outlook is mixed: robust analyst consensus (100% buy ratings) and innovation in data center power solutions offer upside, but high valuations (P/E 48.11) and consecutive earnings misses pose risks. Investors should weigh growth potential against execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
